cs1-peptide and Kidney-Neoplasms

cs1-peptide has been researched along with Kidney-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for cs1-peptide and Kidney-Neoplasms

ArticleYear
Differences in chemotaxis to fibronectin in weakly and highly metastatic tumor cells.
    Japanese journal of cancer research : Gann, 1992, Volume: 83, Issue:12

    We have examined the chemotactic ability of tumor cell lines with different metastatic potential to plasma fibronectin in Transwell chamber assay. Human renal carcinoma cells with highly metastatic potential, SN12 C-2, chemotactically migrated to fibronectin (10 micrograms/ml) about three-fold more strongly than weakly metastatic SN12 C-4 cells. Similarly, murine melanoma B16-BL6 cells (highly metastatic) showed higher motility to soluble fibronectin in comparison with weakly metastatic B16-F1 cells. Anti-VLA-alpha 3 and beta 1 antibodies potently blocked the chemotaxis of both highly and weakly metastatic cells (SN12 C-2 and C-4) to fibronectin. This implies that the migration of both C-2 and C-4 cells to fibronectin is basically mediated by VLA-3 receptor. In contrast, the anti-VLA-alpha 5 antibody and RGDS peptide significantly inhibited the chemotaxis of SN12 C-2 cells to fibronectin, but did not affect weakly metastatic SN12 C-4 cells. These results suggest that the chemotactic ability to fibronectin positively correlates with the metastatic potential in SN12 and B16 cell lines, and that VLA-5 receptor is concerned in the motility of highly metastatic SN12 C-2 cells to soluble fibronectin.

    Topics: Antibodies, Monoclonal; Carcinoma, Renal Cell; Cell Movement; Chemotaxis; Fibronectins; Humans; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Melanoma, Experimental; Oligopeptides; Peptides; Receptors, Fibronectin; Tumor Cells, Cultured

1992